AI in Life Science Analytics Market Report 2026

The AI in life science analytics market size has grown rapidly in recent years. It will grow from $2.63 billion in 2025 to $3.13 billion in 2026 at a compound annual growth rate (CAGR) of 19%. The growth in the historic period can be attributed to increasing volume of clinical and research data, expansion of digital clinical trials, growing use of analytics in pharmaceutical r&d, adoption of data-driven decision making in life sciences, improvements in data integration technologies.

The AI in life science analytics market size is expected to see rapid growth in the next few years. It will grow to $6.16 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, rising investments in ai-enabled drug development, expansion of cloud analytics adoption, growing use of real-world evidence analytics, increasing focus on operational efficiency in life sciences. Major trends in the forecast period include increasing deployment of ai-based clinical analytics tools, rising use of predictive modeling in drug discovery, growing adoption of cloud-based life science analytics, expansion of real-time data integration platforms, enhanced focus on actionable insight generation.

The rising healthcare expenditure is expected to drive the growth of the AI in life science analytics market in the coming years. Healthcare expenditure refers to the total spending on healthcare goods and services within a specific period, including costs related to medical treatment and public health initiatives. The increase in healthcare expenditure is driven by the growing prevalence of chronic and lifestyle-related diseases, which require long-term treatment, ongoing care, and costly interventions. This expenditure supports the adoption of AI in life science analytics by funding advanced data-driven tools that enhance research efficiency, patient outcomes, and cost-effective healthcare solutions. For example, in May 2024, the Office of National Statistics, a UK-based government agency, reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with 0.9% growth in 2022. Thus, rising healthcare expenditure is propelling the growth of the AI in life science analytics market.

Major companies in the AI in life science analytics market are focusing on developing innovative solutions, such as AI-empowered multi-omics data analysis platforms, to accelerate insights and precision in biomedical research. An AI-empowered multi-omics data analysis platform uses artificial intelligence to integrate and analyze diverse biological data types, including genomics, proteomics, and metabolomics, to uncover complex biological insights and support precision medicine. For instance, in October 2023, BioLizard, a Belgium-based biotechnology company, launched the AI-powered BioVerse platform to facilitate data-driven R&D for the global life sciences community. The platform provides tailored, user-friendly software solutions for scientists in biotech and pharma, regardless of IT expertise, and includes applications such as Bio|Reflect, which offers global publication overviews for unbiased literature searches; Pro|Biome, which applies analytics to microbiome data; and Bio|Mx, which leverages AI to integrate and analyze multi-omics datasets. BioVerse aims to support data-driven discovery and preclinical, translational, and clinical R&D processes in the life sciences industry, demonstrating BioLizard’s commitment to AI-driven solutions.

In February 2023, Envision Pharma Group (Envision), a US-based technology company, acquired OKRA.AI for an undisclosed amount. Through this acquisition, Envision strengthened its technological capabilities, providing clients access to advanced AI tools that accelerate decision-making, improve product development, and enhance patient outcomes. OKRA.AI is a UK-based technology company specializing in AI solutions for commercialization, real-world evidence and data analytics, medical affairs, and pricing within the pharmaceutical and life sciences sectors.

Major companies operating in the AI in life science analytics market are Indegene Limited; International Business Machines Corporation; IQVIA Holdings Inc.; Databricks Inc.; SAS Institute Inc.; Sorcero; Atomwise Inc.; Microsoft Corporation; NVIDIA Corporation; Oracle Corporation; NuMedii Inc.; Enlitic Inc.; Apixio Inc.; AiCure LLC; Google LLC; Amazon Web Services Inc.; Accenture; BioSymetrics; Cloud Pharmaceuticals; Freenome; GNS Healthcare; Insilico Medicine; PathAI; Recursion Pharmaceuticals; Sophia Genetics; Veracyte Inc.; Lexalytics Inc.; Sisense Inc.; Cognitivescale; Ayasdi; Cyrcadia Health.

North America was the largest region in the AI in life science analytics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the AI in life science analytics market report during the forecast period. The regions covered in the AI in life science analytics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the AI in life science analytics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the AI in life science analytics market by increasing costs of imported servers, data storage hardware, advanced processors, and networking equipment used in analytics platforms. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported enterprise-grade hardware, while Asia-Pacific faces higher costs for analytics infrastructure scaling. These tariffs are increasing implementation costs and delaying analytics modernization initiatives. However, they are also accelerating cloud migration, encouraging local data center investments, and driving development of software-optimized analytics solutions with lower hardware dependency.

The AI in life science analytics market research report is one of a series of new reports that provides AI in life science analytics market statistics, including AI in life science analytics industry global market size, regional shares, competitors with a AI in life science analytics market share, detailed AI in life science analytics market segments, market trends and opportunities, and any further data you may need to thrive in the AI in life science analytics industry. This AI in life science analytics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial Intelligence (AI) in life sciences analytics involves the use of technology to analyze data and transform unstructured information into actionable insights. This technology plays a crucial role in various life sciences applications, including conducting clinical trials, facilitating new drug discoveries, and enhancing the precision and accuracy of disease diagnoses.

The main components of the AI in life sciences analytics market include software, hardware, and services. Software encompasses applications, scripts, data, programs, or sets of instructions that operate computers and execute specific tasks in the life sciences sector. These software applications are utilized for data management, quality management, sales enablement, drug discovery, and other purposes. They can be deployed on-premises or in the cloud and are applied in various applications such as research and development, sales and marketing support, supply chain analytics, and more. The end-users of AI in life sciences analytics include medical devices, pharmaceuticals, biotechnology, and other related industries.

The AI in the life science analytics market includes revenues earned by entities by providing predictive analytics, prescriptive analytics, and cognitive analytics services. The market value includes the value of related goods sold by the service provider or included within the service offering. AI in the life science analytics market also includes sales of target identification, target validation, and clinical decision support hardware. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.